Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents

Cancer Cell

Volumn 28, Issue 6, 2015, Pages 690-714

  Galluzzi, Lorenzo ^a,b,c,d,e   Buqué, Aitziber ^a,b,c,d,e   Kepp, Oliver ^a,b,c,d,e   Zitvogel, Laurence ^b,e,f,g   Kroemer, Guido ^{a,b,c,d,e,h,i}  

^a CENTRE DE RECHERCHE DES CORDELIERS   (France)

^b INSERM   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d SORBONNE UNIVERSITÉ   (France)

^e INSTITUT GUSTAVE ROUSSY   (France)

^f Center of Clinical Investigations in Biotherapies of Cancer CICBT 507   (France)

^g UNIVERSITÉ PARIS SACLAY   (France)

^h HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

ⁱ KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Checkpoint blockade; Immune contexture; Immunogenic cell death; Natural killer cells; Tumor associated macrophages; Tumor infiltrating lymphocytes

Indexed keywords

ANTINEOPLASTIC AGENT; IMMUNOLOGIC FACTOR;

CANCER CELL; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER THERAPY; CLINICAL PRACTICE; CYTOTOXICITY; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOGENICITY; IMMUNOSTIMULATION; IMMUNOSURVEILLANCE; PRIORITY JOURNAL; REVIEW; ANIMAL; DRUG EFFECTS; IMMUNOLOGY; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PATHOLOGY; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TUMOR ASSOCIATED LEUKOCYTE; TUMOR ESCAPE; TUMOR MICROENVIRONMENT;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; IMMUNOLOGIC FACTORS; LYMPHOCYTES, TUMOR-INFILTRATING; MOLECULAR TARGETED THERAPY; NEOPLASMS; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TUMOR ESCAPE; TUMOR MICROENVIRONMENT;

EID: 84956607773     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccell.2015.10.012     Document Type: Review

References (210)

1. Alizadeh D., Trad M., Hanke N.T., Larmonier C.B., Janikashvili N., Bonnotte B., Katsanis E., Larmonier N. Doxorubicin eliminates myeloid-derived suppressor cells and enhances the efficacy of adoptive T-cell transfer in breast cancer. Cancer Res. 2014, 74:104-118.
2. Amiel E., Everts B., Fritz D., Beauchamp S., Ge B., Pearce E.L., Pearce E.J. Mechanistic target of rapamycin inhibition extends cellular lifespan in dendritic cells by preserving mitochondrial function. J. Immunol. 2014, 193:2821-2830.
3. Anitei M.G., Zeitoun G., Mlecnik B., Marliot F., Haicheur N., Todosi A.M., Kirilovsky A., Lagorce C., Bindea G., Ferariu D., et al. Prognostic and predictive values of the immunoscore in patients with rectal cancer. Clin. Cancer Res. 2014, 20:1891-1899.
4. Ansell S.M., Lesokhin A.M., Borrello I., Halwani A., Scott E.C., Gutierrez M., Schuster S.J., Millenson M.M., Cattry D., Freeman G.J., et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N. Engl. J. Med. 2015, 372:311-319.
5. Anthony D.A., Andrews D.M., Watt S.V., Trapani J.A., Smyth M.J. Functional dissection of the granzyme family: cell death and inflammation. Immunol. Rev. 2010, 235:73-92.
6. Apetoh L., Ghiringhelli F., Tesniere A., Obeid M., Ortiz C., Criollo A., Mignot G., Maiuri M.C., Ullrich E., Saulnier P., et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat. Med. 2007, 13:1050-1059.
7. Aranda F., Bloy N., Pesquet J., Petit B., Chaba K., Sauvat A., Kepp O., Khadra N., Enot D., Pfirschke C., et al. Immune-dependent antineoplastic effects of cisplatin plus pyridoxine in non-small-cell lung cancer. Oncogene 2015, 34:3053-3062.
8. Ascierto P.A., Capone M., Urba W.J., Bifulco C.B., Botti G., Lugli A., Marincola F.M., Ciliberto G., Galon J., Fox B.A. The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment. J. Transl. Med. 2013, 11:54.
9. Atefi M., Avramis E., Lassen A., Wong D.J., Robert L., Foulad D., Cerniglia M., Titz B., Chodon T., Graeber T.G., et al. Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma. Clin. Cancer Res. 2014, 20:3446-3457.
10. Balachandran V.P., Cavnar M.J., Zeng S., Bamboat Z.M., Ocuin L.M., Obaid H., Sorenson E.C., Popow R., Ariyan C., Rossi F., et al. Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat. Med. 2011, 17:1094-1100.
11. Bauer C., Sterzik A., Bauernfeind F., Duewell P., Conrad C., Kiefl R., Endres S., Eigler A., Schnurr M., Dauer M. Concomitant gemcitabine therapy negatively affects DC vaccine-induced CD8(+) T-cell and B-cell responses but improves clinical efficacy in a murine pancreatic carcinoma model. Cancer Immunol. Immunother. 2014, 63:321-333.
12. Bezu L., Gomes-de-Silva L.C., Dewitte H., Breckpot K., Fucikova J., Spisek R., Galluzzi L., Kepp O., Kroemer G. Combinatorial strategies for the induction of immunogenic cell death. Front. Immunol. 2015, 6:187.
13. Bloy N., Pol J., Aranda F., Eggermont A., Cremer I., Fridman W.H., Fučíková J., Galon J., Tartour E., Spisek R., et al. Trial watch: Dendritic cell-based anticancer therapy. OncoImmunology 2014, 3:e963424.
14. Borg C., Terme M., Taïeb J., Ménard C., Flament C., Robert C., Maruyama K., Wakasugi H., Angevin E., Thielemans K., et al. Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. J. Clin. Invest. 2004, 114:379-388.
15. Bracci L., Schiavoni G., Sistigu A., Belardelli F. Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer. Cell Death Differ. 2014, 21:15-25.
16. Brenner C., Galluzzi L., Kepp O., Kroemer G. Decoding cell death signals in liver inflammation. J. Hepatol. 2013, 59:583-594.
17. Broz M.L., Binnewies M., Boldajipour B., Nelson A.E., Pollack J.L., Erle D.J., Barczak A., Rosenblum M.D., Daud A., Barber D.L., et al. Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. Cancer Cell 2014, 26:638-652.
18. Bruchard M., Mignot G., Derangère V., Chalmin F., Chevriaux A., Végran F., Boireau W., Simon B., Ryffel B., Connat J.L., et al. Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth. Nat. Med. 2013, 19:57-64.
19. Bugaut H., Bruchard M., Berger H., Derangère V., Odoul L., Euvrard R., Ladoire S., Chalmin F., Végran F., Rébé C., et al. Bleomycin exerts ambivalent antitumor immune effect by triggering both immunogenic cell death and proliferation of regulatory T cells. PLoS ONE 2013, 8:e65181.
20. Byrd J.C., O'Brien S., James D.F. Ibrutinib in relapsed chronic lymphocytic leukemia. N. Engl. J. Med. 2013, 369:1278-1279.
21. Cao K., Wang G., Li W., Zhang L., Wang R., Huang Y., Du L., Jiang J., Wu C., He X., et al. Histone deacetylase inhibitors prevent activation-induced cell death and promote anti-tumor immunity. Oncogene 2015, Published online March 9, 2015. 10.1038/onc.2015.46.
22. Carragher D.M., Rangel-Moreno J., Randall T.D. Ectopic lymphoid tissues and local immunity. Semin. Immunol. 2008, 20:26-42.
23. Casares N., Pequignot M.O., Tesniere A., Ghiringhelli F., Roux S., Chaput N., Schmitt E., Hamai A., Hervas-Stubbs S., Obeid M., et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J. Exp. Med. 2005, 202:1691-1701.
24. Cavnar M.J., Zeng S., Kim T.S., Sorenson E.C., Ocuin L.M., Balachandran V.P., Seifert A.M., Greer J.B., Popow R., Crawley M.H., et al. KIT oncogene inhibition drives intratumoral macrophage M2 polarization. J. Exp. Med. 2013, 210:2873-2886.
25. Chen C., Chen Z., Chen D., Zhang B., Wang Z., Le H. Suppressive effects of gemcitabine plus cisplatin chemotherapy on regulatory T cells in nonsmall-cell lung cancer. J. Int. Med. Res. 2015, 43:180-187.
26. Chiappinelli K.B., Strissel P.L., Desrichard A., Li H., Henke C., Akman B., Hein A., Rote N.S., Cope L.M., Snyder A., et al. Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses. Cell 2015, 162:974-986.
27. Choueiri T.K., Figueroa D.J., Fay A.P., Signoretti S., Liu Y., Gagnon R., Deen K., Carpenter C., Benson P., Ho T.H., et al. Correlation of PD-L1 tumor expression and treatment outcomes in patients with renal cell carcinoma receiving sunitinib or pazopanib: results from COMPARZ, a randomized controlled trial. Clin. Cancer Res. 2015, 21:1071-1077.
28. Chow J., Franz K.M., Kagan J.C. PRRs are watching you: Localization of innate sensing and signaling regulators. Virology 2015, 479-480:104-109.
29. Chuang H.Y., Chang Y.F., Liu R.S., Hwang J.J. Serial low doses of sorafenib enhance therapeutic efficacy of adoptive T cell therapy in a murine model by improving tumor microenvironment. PLoS ONE 2014, 9:e109992.
30. Cooper Z.A., Frederick D.T., Juneja V.R., Sullivan R.J., Lawrence D.P., Piris A., Sharpe A.H., Fisher D.E., Flaherty K.T., Wargo J.A. BRAF inhibition is associated with increased clonality in tumor-infiltrating lymphocytes. OncoImmunology 2013, 2:e26615.
31. Coussens L.M., Zitvogel L., Palucka A.K. Neutralizing tumor-promoting chronic inflammation: a magic bullet?. Science 2013, 339:286-291.
32. Cribbs A.P., Kennedy A., Penn H., Amjadi P., Green P., Read J.E., Brennan F., Gregory B., Williams R.O. Methotrexate restores regulatory T cell function through demethylation of the FoxP3 upstream enhancer in patients with rheumatoid arthritis. Arthritis Rheumatol. 2015, 67:1182-1192.
33. Cullen S.P., Kearney C.J., Clancy D.M., Martin S.J. Diverse Activators of the NLRP3 Inflammasome Promote IL-1β Secretion by Triggering Necrosis. Cell Rep. 2015, 11:1535-1548.
34. Davis M., Conlon K., Bohac G.C., Barcenas J., Leslie W., Watkins L., Lamzabi I., Deng Y., Li Y., Plate J.M. Effect of pemetrexed on innate immune killer cells and adaptive immune T cells in subjects with adenocarcinoma of the pancreas. J. Immunother. 2012, 35:629-640.
35. de Bruyn M., Wiersma V.R., Helfrich W., Eggleton P., Bremer E. The ever-expanding immunomodulatory role of calreticulin in cancer immunity. Front. Oncol. 2015, 5:35.
36. De Monte L., Reni M., Tassi E., Clavenna D., Papa I., Recalde H., Braga M., Di Carlo V., Doglioni C., Protti M.P. Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer. J. Exp. Med. 2011, 208:469-478.
37. Delahaye N.F., Rusakiewicz S., Martins I., Ménard C., Roux S., Lyonnet L., Paul P., Sarabi M., Chaput N., Semeraro M., et al. Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors. Nat. Med. 2011, 17:700-707.
38. Demaria S., Volm M.D., Shapiro R.L., Yee H.T., Oratz R., Formenti S.C., Muggia F., Symmans W.F. Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy. Clin. Cancer Res. 2001, 7:3025-3030.
39. DeNardo D.G., Brennan D.J., Rexhepaj E., Ruffell B., Shiao S.L., Madden S.F., Gallagher W.M., Wadhwani N., Keil S.D., Junaid S.A., et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov. 2011, 1:54-67.
40. Denkert C., Loibl S., Noske A., Roller M., Müller B.M., Komor M., Budczies J., Darb-Esfahani S., Kronenwett R., Hanusch C., et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J. Clin. Oncol. 2010, 28:105-113.
41. Denkert C., von Minckwitz G., Brase J.C., Sinn B.V., Gade S., Kronenwett R., Pfitzner B.M., Salat C., Loi S., Schmitt W.D., et al. Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. J. Clin. Oncol. 2015, 33:983-991.
42. Desar I.M., Jacobs J.H., Hulsbergen-vandeKaa C.A., Oyen W.J., Mulders P.F., van der Graaf W.T., Adema G.J., van Herpen C.M., de Vries I.J. Sorafenib reduces the percentage of tumour infiltrating regulatory T cells in renal cell carcinoma patients. Int. J. Cancer 2011, 129:507-512.
43. Di Caro G., Cortese N., Castino G.F., Grizzi F., Gavazzi F., Ridolfi C., Capretti G., Mineri R., Todoric J., Zerbi A., et al. Dual prognostic significance of tumour-associated macrophages in human pancreatic adenocarcinoma treated or untreated with chemotherapy. Gut 2015, 10.1136/gutjnl-2015-309193.
44. Dieu-Nosjean M.C., Antoine M., Danel C., Heudes D., Wislez M., Poulot V., Rabbe N., Laurans L., Tartour E., de Chaisemartin L., et al. Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J. Clin. Oncol. 2008, 26:4410-4417.
45. Dimeloe S., Frick C., Fischer M., Gubser P.M., Razik L., Bantug G.R., Ravon M., Langenkamp A., Hess C. Human regulatory T cells lack the cyclophosphamide-extruding transporter ABCB1 and are more susceptible to cyclophosphamide-induced apoptosis. Eur. J. Immunol. 2014, 44:3614-3620.
46. Ding Z.C., Lu X., Yu M., Lemos H., Huang L., Chandler P., Liu K., Walters M., Krasinski A., Mack M., et al. Immunosuppressive myeloid cells induced by chemotherapy attenuate antitumor CD4+ T-cell responses through the PD-1-PD-L1 axis. Cancer Res. 2014, 74:3441-3453.
47. Druker B.J. Perspectives on the development of imatinib and the future of cancer research. Nat. Med. 2009, 15:1149-1152.
48. Dubovsky J.A., Beckwith K.A., Natarajan G., Woyach J.A., Jaglowski S., Zhong Y., Hessler J.D., Liu T.M., Chang B.Y., Larkin K.M., et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood 2013, 122:2539-2549.
49. Dudek-Perić A.M., Ferreira G.B., Muchowicz A., Wouters J., Prada N., Martin S., Kiviluoto S., Winiarska M., Boon L., Mathieu C., et al. Antitumor immunity triggered by melphalan is potentiated by melanoma cell surface-associated calreticulin. Cancer Res. 2015, 75:1603-1614.
50. Escamilla J., Schokrpur S., Liu C., Priceman S.J., Moughon D., Jiang Z., Pouliot F., Magyar C., Sung J.L., Xu J., et al. CSF1 receptor targeting in prostate cancer reverses macrophage-mediated resistance to androgen blockade therapy. Cancer Res. 2015, 75:950-962.
51. Ferlazzo G., Morandi B. Cross-Talks between Natural Killer Cells and Distinct Subsets of Dendritic Cells. Front. Immunol. 2014, 5:159.
52. Ferrari de Andrade L., Ngiow S.F., Stannard K., Rusakiewicz S., Kalimutho M., Khanna K.K., Tey S.K., Takeda K., Zitvogel L., Martinet L., Smyth M.J. Natural killer cells are essential for the ability of BRAF inhibitors to control BRAFV600E-mutant metastatic melanoma. Cancer Res. 2014, 74:7298-7308.
53. Finn O.J. Cancer immunology. N. Engl. J. Med. 2008, 358:2704-2715.
54. Frederick D.T., Piris A., Cogdill A.P., Cooper Z.A., Lezcano C., Ferrone C.R., Mitra D., Boni A., Newton L.P., Liu C., et al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin. Cancer Res. 2013, 19:1225-1231.
55. Fridman W.H., Pagès F., Sautès-Fridman C., Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat. Rev. Cancer 2012, 12:298-306.
56. Fulda S., Galluzzi L., Kroemer G. Targeting mitochondria for cancer therapy. Nat. Rev. Drug Discov. 2010, 9:447-464.
57. Gabrilovich D.I., Ostrand-Rosenberg S., Bronte V. Coordinated regulation of myeloid cells by tumours. Nat. Rev. Immunol. 2012, 12:253-268.
58. Galluzzi L., Senovilla L., Zitvogel L., Kroemer G. The secret ally: immunostimulation by anticancer drugs. Nat. Rev. Drug Discov. 2012, 11:215-233.
59. Galluzzi L., Bravo-San Pedro J.M., Vitale I., Aaronson S.A., Abrams J.M., Adam D., Alnemri E.S., Altucci L., Andrews D., Annicchiarico-Petruzzelli M., et al. Essential versus accessory aspects of cell death: recommendations of the NCCD 2015. Cell Death Differ. 2015, 22:58-73.
60. Gambacorti-Passerini C., Kantarjian H.M., Kim D.W., Khoury H.J., Turkina A.G., Brümmendorf T.H., Matczak E., Bardy-Bouxin N., Shapiro M., Turnbull K., et al. Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors. Am. J. Hematol. 2015, 90:755-768.
61. Garrido G., Rabasa A., Sánchez B., López M.V., Blanco R., López A., Hernández D.R., Pérez R., Fernández L.E. Induction of immunogenic apoptosis by blockade of epidermal growth factor receptor activation with a specific antibody. J. Immunol. 2011, 187:4954-4966.
62. Geary S.M., Lemke C.D., Lubaroff D.M., Salem A.K. The combination of a low-dose chemotherapeutic agent, 5-fluorouracil, and an adenoviral tumor vaccine has a synergistic benefit on survival in a tumor model system. PLoS ONE 2013, 8:e67904.
63. Gershan J.A., Barr K.M., Weber J.J., Jing W., Johnson B.D. Immune modulating effects of cyclophosphamide and treatment with tumor lysate/CpG synergize to eliminate murine neuroblastoma. J. Immunother. Cancer 2015, 3:24.
64. Ghiringhelli F., Larmonier N., Schmitt E., Parcellier A., Cathelin D., Garrido C., Chauffert B., Solary E., Bonnotte B., Martin F. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur. J. Immunol. 2004, 34:336-344.
65. Ghiringhelli F., Menard C., Puig P.E., Ladoire S., Roux S., Martin F., Solary E., Le Cesne A., Zitvogel L., Chauffert B. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol. Immunother. 2007, 56:641-648.
66. Ghiringhelli F., Apetoh L., Tesniere A., Aymeric L., Ma Y., Ortiz C., Vermaelen K., Panaretakis T., Mignot G., Ullrich E., et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat. Med. 2009, 15:1170-1178.
67. Gjerdrum L.M., Woetmann A., Odum N., Burton C.M., Rossen K., Skovgaard G.L., Ryder L.P., Ralfkiaer E. FOXP3+ regulatory T cells in cutaneous T-cell lymphomas: association with disease stage and survival. Leukemia 2007, 21:2512-2518.
68. Goeppert B., Frauenschuh L., Zucknick M., Stenzinger A., Andrulis M., Klauschen F., Joehrens K., Warth A., Renner M., Mehrabi A., et al. Prognostic impact of tumour-infiltrating immune cells on biliary tract cancer. Br. J. Cancer 2013, 109:2665-2674.
69. Gonzalez-Aparicio M., Alzuguren P., Mauleon I., Medina-Echeverz J., Hervas-Stubbs S., Mancheno U., Berraondo P., Crettaz J., Gonzalez-Aseguinolaza G., Prieto J., Hernandez-Alcoceba R. Oxaliplatin in combination with liver-specific expression of interleukin 12 reduces the immunosuppressive microenvironment of tumours and eradicates metastatic colorectal cancer in mice. Gut 2011, 60:341-349.
70. Gubin M.M., Zhang X., Schuster H., Caron E., Ward J.P., Noguchi T., Ivanova Y., Hundal J., Arthur C.D., Krebber W.J., et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 2014, 515:577-581.
71. Halleck F., Budde K. Transplantation: Sirolimus for secondary SCC prevention in renal transplantation. Nat. Rev. Nephrol. 2012, 8:687-689.
72. Hamilton R., Krauze M., Romkes M., Omolo B., Konstantinopoulos P., Reinhart T., Harasymczuk M., Wang Y., Lin Y., Ferrone S., et al. Pathologic and gene expression features of metastatic melanomas to the brain. Cancer 2013, 119:2737-2746.
73. Han L.Y., Fletcher M.S., Urbauer D.L., Mueller P., Landen C.N., Kamat A.A., Lin Y.G., Merritt W.M., Spannuth W.A., Deavers M.T., et al. HLA class I antigen processing machinery component expression and intratumoral T-Cell infiltrate as independent prognostic markers in ovarian carcinoma. Clin. Cancer Res. 2008, 14:3372-3379.
74. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
75. Hannesdóttir L., Tymoszuk P., Parajuli N., Wasmer M.H., Philipp S., Daschil N., Datta S., Koller J.B., Tripp C.H., Stoitzner P., et al. Lapatinib and doxorubicin enhance the Stat1-dependent antitumor immune response. Eur. J. Immunol. 2013, 43:2718-2729.
76. He S., Yin T., Li D., Gao X., Wan Y., Ma X., Ye T., Guo F., Sun J., Lin Z., Wang Y. Enhanced interaction between natural killer cells and lung cancer cells: involvement in gefitinib-mediated immunoregulation. J. Transl. Med. 2013, 11:186.
77. Ho P.C., Meeth K.M., Tsui Y.C., Srivastava B., Bosenberg M.W., Kaech S.M. Immune-based antitumor effects of BRAF inhibitors rely on signaling by CD40L and IFNγ. Cancer Res. 2014, 74:3205-3217.
78. Hodge J.W., Garnett C.T., Farsaci B., Palena C., Tsang K.Y., Ferrone S., Gameiro S.R. Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death. Int. J. Cancer 2013, 133:624-636.
79. Homma Y., Taniguchi K., Nakazawa M., Matsuyama R., Mori R., Takeda K., Ichikawa Y., Tanaka K., Endo I. Changes in the immune cell population and cell proliferation in peripheral blood after gemcitabine-based chemotherapy for pancreatic cancer. Clin. Transl. Oncol. 2014, 16:330-335.
80. Huang Y., Yuan J., Righi E., Kamoun W.S., Ancukiewicz M., Nezivar J., Santosuosso M., Martin J.D., Martin M.R., Vianello F., et al. Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc. Natl. Acad. Sci. USA 2012, 109:17561-17566.
81. Huang H., Langenkamp E., Georganaki M., Loskog A., Fuchs P.F., Dieterich L.C., Kreuger J., Dimberg A. VEGF suppresses T-lymphocyte infiltration in the tumor microenvironment through inhibition of NF-κB-induced endothelial activation. FASEB J. 2015, 29:227-238.
82. Iida N., Dzutsev A., Stewart C.A., Smith L., Bouladoux N., Weingarten R.A., Molina D.A., Salcedo R., Back T., Cramer S., et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science 2013, 342:967-970.
83. Iriyama N., Fujisawa S., Yoshida C., Wakita H., Chiba S., Okamoto S., Kawakami K., Takezako N., Kumagai T., Inokuchi K., et al. Early cytotoxic lymphocyte expansion contributes to a deep molecular response to dasatinib in patients with newly diagnosed chronic myeloid leukemia in the chronic phase: results of the D-first study. Am. J. Hematol. 2015, 90:819-824.
84. Issa-Nummer Y., Darb-Esfahani S., Loibl S., Kunz G., Nekljudova V., Schrader I., Sinn B.V., Ulmer H.U., Kronenwett R., Just M., et al. Prospective validation of immunological infiltrate for prediction of response to neoadjuvant chemotherapy in HER2-negative breast cancer--a substudy of the neoadjuvant GeparQuinto trial. PLoS ONE 2013, 8:e79775.
85. Jayson G.C., Hicklin D.J., Ellis L.M. Antiangiogenic therapy--evolving view based on clinical trial results. Nat. Rev. Clin. Oncol. 2012, 9:297-303.
86. Jenq R.R., van den Brink M.R. Allogeneic haematopoietic stem cell transplantation: individualized stem cell and immune therapy of cancer. Nat. Rev. Cancer 2010, 10:213-221.
87. Jung A.C., Guihard S., Krugell S., Ledrappier S., Brochot A., Dalstein V., Job S., de Reynies A., Noël G., Wasylyk B., et al. CD8-alpha T-cell infiltration in human papillomavirus-related oropharyngeal carcinoma correlates with improved patient prognosis. Int. J. Cancer 2013, 132:E26-E36.
88. Kakavand H., Wilmott J.S., Menzies A.M., Vilain R., Haydu L.E., Yearley J.H., Thompson J.F., Kefford R.F., Hersey P., Long G.V., et al. PD-L1 expression and tumor-infiltrating lymphocytes define different subsets of MAPK inhibitor-treated melanoma patients. Clin Cancer Res. 2015, 21:3140-3148.
89. Kang T.H., Mao C.P., Lee S.Y., Chen A., Lee J.H., Kim T.W., Alvarez R.D., Roden R.B., Pardoll D., Hung C.F., Wu T.C. Chemotherapy acts as an adjuvant to convert the tumor microenvironment into a highly permissive state for vaccination-induced antitumor immunity. Cancer Res. 2013, 73:2493-2504.
90. Kanterman J., Sade-Feldman M., Biton M., Ish-Shalom E., Lasry A., Goldshtein A., Hubert A., Baniyash M. Adverse immunoregulatory effects of 5FU and CPT11 chemotherapy on myeloid-derived suppressor cells and colorectal cancer outcomes. Cancer Res. 2014, 74:6022-6035.
91. Kasajima A., Sers C., Sasano H., Jöhrens K., Stenzinger A., Noske A., Buckendahl A.C., Darb-Esfahani S., Müller B.M., Budczies J., et al. Down-regulation of the antigen processing machinery is linked to a loss of inflammatory response in colorectal cancer. Hum. Pathol. 2010, 41:1758-1769.
92. Kawakami Y., Inagaki N., Salek-Ardakani S., Kitaura J., Tanaka H., Nagao K., Kawakami Y., Xiao W., Nagai H., Croft M., Kawakami T. Regulation of dendritic cell maturation and function by Bruton's tyrosine kinase via IL-10 and Stat3. Proc. Natl. Acad. Sci. USA 2006, 103:153-158.
93. Kelley T.W., Pohlman B., Elson P., Hsi E.D. The ratio of FOXP3+ regulatory T cells to granzyme B+ cytotoxic T/NK cells predicts prognosis in classical Hodgkin lymphoma and is independent of bcl-2 and MAL expression. Am. J. Clin. Pathol. 2007, 128:958-965.
94. Kepp O., Senovilla L., Vitale I., Vacchelli E., Adjemian S., Agostinis P., Apetoh L., Aranda F., Barnaba V., Bloy N., et al. Consensus guidelines for the detection of immunogenic cell death. OncoImmunology 2014, 3:e955691.
95. Khallouf H., Märten A., Serba S., Teichgräber V., Büchler M.W., Jäger D., Schmidt J. 5-Fluorouracil and interferon-α immunochemotherapy enhances immunogenicity of murine pancreatic cancer through upregulation of NKG2D ligands and MHC class I. J. Immunother. 2012, 35:245-253.
96. Kim H., Kim S.H., Kim M.J., Kim S.J., Park S.J., Chung J.S., Bae J.H., Kang C.D. EGFR inhibitors enhanced the susceptibility to NK cell-mediated lysis of lung cancer cells. J. Immunother. 2011, 34:372-381.
97. Kim K., Skora A.D., Li Z., Liu Q., Tam A.J., Blosser R.L., Diaz L.A., Papadopoulos N., Kinzler K.W., Vogelstein B., Zhou S. Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells. Proc. Natl. Acad. Sci. USA 2014, 111:11774-11779.
98. Knight D.A., Ngiow S.F., Li M., Parmenter T., Mok S., Cass A., Haynes N.M., Kinross K., Yagita H., Koya R.C., et al. Host immunity contributes to the anti-melanoma activity of BRAF inhibitors. J. Clin. Invest. 2013, 123:1371-1381.
99. Kremer J.M. Therapy: methotrexate guidelines: compromise to reach consensus. Nat. Rev. Rheumatol. 2009, 5:186-187.
100. Kroemer G., Galluzzi L., Kepp O., Zitvogel L. Immunogenic cell death in cancer therapy. Annu. Rev. Immunol. 2013, 31:51-72.
101. Krysko D.V., Garg A.D., Kaczmarek A., Krysko O., Agostinis P., Vandenabeele P. Immunogenic cell death and DAMPs in cancer therapy. Nat. Rev. Cancer 2012, 12:860-875.
102. Kumagai T., Matsuki E., Inokuchi K., Ohashi K., Shinagawa A., Takeuchi J., Yoshida C., Okamoto S., Wakita H., Kozai Y., et al. Relative increase in lymphocytes from as early as 1 month predicts improved response to dasatinib in chronic-phase chronic myelogenous leukemia. Int. J. Hematol. 2014, 99:41-52.
103. Kurts C., Robinson B.W., Knolle P.A. Cross-priming in health and disease. Nat. Rev. Immunol. 2010, 10:403-414.
104. Ladoire S., Mignot G., Dabakuyo S., Arnould L., Apetoh L., Rébé C., Coudert B., Martin F., Bizollon M.H., Vanoli A., et al. In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival. J. Pathol. 2011, 224:389-400.
105. Lesokhin A.M., Callahan M.K., Postow M.A., Wolchok J.D. On being less tolerant: enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation. Sci. Transl. Med. 2015, 7:280sr1.
106. Lesterhuis W.J., Punt C.J., Hato S.V., Eleveld-Trancikova D., Jansen B.J., Nierkens S., Schreibelt G., de Boer A., Van Herpen C.M., Kaanders J.H., et al. Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice. J. Clin. Invest. 2011, 121:3100-3108.
107. Lesterhuis W.J., Salmons J., Nowak A.K., Rozali E.N., Khong A., Dick I.M., Harken J.A., Robinson B.W., Lake R.A. Synergistic effect of CTLA-4 blockade and cancer chemotherapy in the induction of anti-tumor immunity. PLoS ONE 2013, 8:e61895.
108. Li H., Chiappinelli K.B., Guzzetta A.A., Easwaran H., Yen R.W., Vatapalli R., Topper M.J., Luo J., Connolly R.M., Azad N.S., et al. Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers. Oncotarget 2014, 5:587-598.
109. Li J.Y., Duan X.F., Wang L.P., Xu Y.J., Huang L., Zhang T.F., Liu J.Y., Li F., Zhang Z., Yue D.L., et al. Selective depletion of regulatory T cell subsets by docetaxel treatment in patients with nonsmall cell lung cancer. J. Immunol. Res. 2014, 2014:286170.
110. Liechtenstein T., Perez-Janices N., Gato M., Caliendo F., Kochan G., Blanco-Luquin I., Van der Jeught K., Arce F., Guerrero-Setas D., Fernandez-Irigoyen J., et al. A highly efficient tumor-infiltrating MDSC differentiation system for discovery of anti-neoplastic targets, which circumvents the need for tumor establishment in mice. Oncotarget 2014, 5:7843-7857.
111. Lim S.H., Chua W., Cheng C., Descallar J., Ng W., Solomon M., Bokey L., Wong K., Lee M.T., de Souza P., et al. Effect of neoadjuvant chemoradiation on tumor-infiltrating/associated lymphocytes in locally advanced rectal cancers. Anticancer Res. 2014, 34:6505-6513.
112. Litvin O., Schwartz S., Wan Z., Schild T., Rocco M., Oh N.L., Chen B.J., Goddard N., Pratilas C., Pe'er D. Interferon α/β Enhances the Cytotoxic Response of MEK Inhibition in Melanoma. Mol. Cell 2015, 57:784-796.
113. Liu W.M., Fowler D.W., Smith P., Dalgleish A.G. Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses. Br. J. Cancer 2010, 102:115-123.
114. Liu C., Peng W., Xu C., Lou Y., Zhang M., Wargo J.A., Chen J.Q., Li H.S., Watowich S.S., Yang Y., et al. BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice. Clin. Cancer Res. 2013, 19:393-403.
115. Liu L., Mayes P.A., Eastman S., Shi H., Yadavilli S., Zhang T., Yang J., Seestaller-Wehr L., Zhang S.Y., Hopson C., et al. The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4. Clin. Cancer Res. 2015, 21:1639-1651.
116. Lowe D.B., Bose A., Taylor J.L., Tawbi H., Lin Y., Kirkwood J.M., Storkus W.J. Dasatinib promotes the expansion of a therapeutically superior T-cell repertoire in response to dendritic cell vaccination against melanoma. OncoImmunology 2014, 3:e27589.
117. Luo J., Solimini N.L., Elledge S.J. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 2009, 136:823-837.
118. Lynch T.J., Bondarenko I., Luft A., Serwatowski P., Barlesi F., Chacko R., Sebastian M., Neal J., Lu H., Cuillerot J.M., Reck M. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J. Clin. Oncol. 2012, 30:2046-2054.
119. Ma Y., Aymeric L., Locher C., Kroemer G., Zitvogel L. The dendritic cell-tumor cross-talk in cancer. Curr. Opin. Immunol. 2011, 23:146-152.
120. Ma Y., Aymeric L., Locher C., Mattarollo S.R., Delahaye N.F., Pereira P., Boucontet L., Apetoh L., Ghiringhelli F., Casares N., et al. Contribution of IL-17-producing gamma delta T cells to the efficacy of anticancer chemotherapy. J. Exp. Med. 2011, 208:491-503.
121. Ma Y., Adjemian S., Mattarollo S.R., Yamazaki T., Aymeric L., Yang H., Portela Catani J.P., Hannani D., Duret H., Steegh K., et al. Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. Immunity 2013, 38:729-741.
122. Ma Y., Mattarollo S.R., Adjemian S., Yang H., Aymeric L., Hannani D., Portela Catani J.P., Duret H., Teng M.W., Kepp O., et al. CCL2/CCR2-dependent recruitment of functional antigen-presenting cells into tumors upon chemotherapy. Cancer Res. 2014, 74:436-445.
123. Martins I., Kepp O., Schlemmer F., Adjemian S., Tailler M., Shen S., Michaud M., Menger L., Gdoura A., Tajeddine N., et al. Restoration of the immunogenicity of cisplatin-induced cancer cell death by endoplasmic reticulum stress. Oncogene 2011, 30:1147-1158.
124. Matzinger P. Tolerance, danger, and the extended family. Annu. Rev. Immunol. 1994, 12:991-1045.
125. McDonnell A.M., Lesterhuis W.J., Khong A., Nowak A.K., Lake R.A., Currie A.J., Robinson B.W. Tumor-infiltrating dendritic cells exhibit defective cross-presentation of tumor antigens, but is reversed by chemotherapy. Eur. J. Immunol. 2015, 45:49-59.
126. Ménard C., Blay J.Y., Borg C., Michiels S., Ghiringhelli F., Robert C., Nonn C., Chaput N., Taïeb J., Delahaye N.F., et al. Natural killer cell IFN-gamma levels predict long-term survival with imatinib mesylate therapy in gastrointestinal stromal tumor-bearing patients. Cancer Res. 2009, 69:3563-3569.
127. Menger L., Vacchelli E., Adjemian S., Martins I., Ma Y., Shen S., Yamazaki T., Sukkurwala A.Q., Michaud M., Mignot G., et al. Cardiac glycosides exert anticancer effects by inducing immunogenic cell death. Sci. Transl. Med. 2012, 4:143ra99.
128. Michaud M., Martins I., Sukkurwala A.Q., Adjemian S., Ma Y., Pellegatti P., Shen S., Kepp O., Scoazec M., Mignot G., et al. Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science 2011, 334:1573-1577.
129. Mignot G., Hervieu A., Vabres P., Dalac S., Jeudy G., Bel B., Apetoh L., Ghiringhelli F. Prospective study of the evolution of blood lymphoid immune parameters during dacarbazine chemotherapy in metastatic and locally advanced melanoma patients. PLoS ONE 2014, 9:e105907.
130. Mitchem J.B., Brennan D.J., Knolhoff B.L., Belt B.A., Zhu Y., Sanford D.E., Belaygorod L., Carpenter D., Collins L., Piwnica-Worms D., et al. Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses. Cancer Res. 2013, 73:1128-1141.
131. Mittendorf E.A., Philips A.V., Meric-Bernstam F., Qiao N., Wu Y., Harrington S., Su X., Wang Y., Gonzalez-Angulo A.M., Akcakanat A., et al. PD-L1 expression in triple-negative breast cancer. Cancer Immunol. Res. 2014, 2:361-370.
132. Mizoguchi I., Yoshimoto T., Katagiri S., Mizuguchi J., Tauchi T., Kimura Y., Inokuchi K., Ohyashiki J.H., Ohyashiki K. Sustained upregulation of effector natural killer cells in chronic myeloid leukemia after discontinuation of imatinib. Cancer Sci. 2013, 104:1146-1153.
133. Mohammed Z.M., Going J.J., Edwards J., Elsberger B., McMillan D.C. The relationship between lymphocyte subsets and clinico-pathological determinants of survival in patients with primary operable invasive ductal breast cancer. Br. J. Cancer 2013, 109:1676-1684.
134. Morisaki T., Hirano T., Koya N., Kiyota A., Tanaka H., Umebayashi M., Onishi H., Katano M. NKG2D-directed cytokine-activated killer lymphocyte therapy combined with gemcitabine for patients with chemoresistant metastatic solid tumors. Anticancer Res. 2014, 34:4529-4538.
135. Mortara L., Orecchia P., Castellani P., Borsi L., Carnemolla B., Balza E. Schedule-dependent therapeutic efficacy of L19mTNF-α and melphalan combined with gemcitabine. Cancer Med. 2013, 2:478-487.
136. Mundy-Bosse B.L., Lesinski G.B., Jaime-Ramirez A.C., Benninger K., Khan M., Kuppusamy P., Guenterberg K., Kondadasula S.V., Chaudhury A.R., La Perle K.M., et al. Myeloid-derived suppressor cell inhibition of the IFN response in tumor-bearing mice. Cancer Res. 2011, 71:5101-5110.
137. Murray J.C., Aldeghaither D., Wang S., Nasto R.E., Jablonski S.A., Tang Y., Weiner L.M. c-Abl modulates tumor cell sensitivity to antibody-dependent cellular cytotoxicity. Cancer Immunol. Res. 2014, 2:1186-1198.
138. Neagu M., Constantin C., Zurac S. Immune parameters in the prognosis and therapy monitoring of cutaneous melanoma patients: experience, role, and limitations. BioMed Res. Int. 2013, 2013:107940.
139. Nelson B.H. New insights into tumor immunity revealed by the unique genetic and genomic aspects of ovarian cancer. Curr. Opin. Immunol. 2015, 33:93-100.
140. Nelson M.A., Shetty S., Kulakodlu M., Harley C., Seal B. A comparison of mortality and costs associated with FOLFOX versus FOLFIRI in stage IV colorectal cancer. J. Med. Econ. 2011, 14:179-186.
141. Ness N., Andersen S., Valkov A., Nordby Y., Donnem T., Al-Saad S., Busund L.T., Bremnes R.M., Richardsen E. Infiltration of CD8+ lymphocytes is an independent prognostic factor of biochemical failure-free survival in prostate cancer. Prostate 2014, 74:1452-1461.
142. Nowak A.K., Lake R.A., Marzo A.L., Scott B., Heath W.R., Collins E.J., Frelinger J.A., Robinson B.W. Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells. J. Immunol. 2003, 170:4905-4913.
143. Obeid M., Tesniere A., Ghiringhelli F., Fimia G.M., Apetoh L., Perfettini J.L., Castedo M., Mignot G., Panaretakis T., Casares N., et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat. Med. 2007, 13:54-61.
144. Park S., Jiang Z., Mortenson E.D., Deng L., Radkevich-Brown O., Yang X., Sattar H., Wang Y., Brown N.K., Greene M., et al. The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell 2010, 18:160-170.
145. Pfannenstiel L.W., Lam S.S., Emens L.A., Jaffee E.M., Armstrong T.D. Paclitaxel enhances early dendritic cell maturation and function through TLR4 signaling in mice. Cell. Immunol. 2010, 263:79-87.
146. Preudhomme C., Guilhot J., Nicolini F.E., Guerci-Bresler A., Rigal-Huguet F., Maloisel F., Coiteux V., Gardembas M., Berthou C., Vekhoff A., et al. Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia. N. Engl. J. Med. 2010, 363:2511-2521. SPIRIT Investigators, France Intergroupe des Leucémies Myéloïdes Chroniques (Fi-LMC)France Intergroupe des Leucémies Myéloïdes Chroniques (Fi-LMC).
147. Rabinovich G.A., Gabrilovich D., Sotomayor E.M. Immunosuppressive strategies that are mediated by tumor cells. Annu. Rev. Immunol. 2007, 25:267-296.
148. Reck M., Bondarenko I., Luft A., Serwatowski P., Barlesi F., Chacko R., Sebastian M., Lu H., Cuillerot J.M., Lynch T.J. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. Ann. Oncol. 2013, 24:75-83.
149. Remark R., Becker C., Gomez J.E., Damotte D., Dieu-Nosjean M.C., Sautès-Fridman C., Fridman W.H., Powell C.A., Altorki N.K., Merad M., Gnjatic S. The non-small cell lung cancer immune contexture. A major determinant of tumor characteristics and patient outcome. Am. J. Respir. Crit. Care Med. 2015, 191:377-390.
150. Riva G., Luppi M., Lagreca I., Barozzi P., Quadrelli C., Vallerini D., Zanetti E., Basso S., Forghieri F., Morselli M., et al. Long-term molecular remission with persistence of BCR-ABL1-specific cytotoxic T cells following imatinib withdrawal in an elderly patient with Philadelphia-positive ALL. Br. J. Haematol. 2014, 164:299-302.
151. Robert C., Karaszewska B., Schachter J., Rutkowski P., Mackiewicz A., Stroiakovski D., Lichinitser M., Dummer R., Grange F., Mortier L., et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N. Engl. J. Med. 2015, 372:30-39.
152. Romero A.I., Chaput N., Poirier-Colame V., Rusakiewicz S., Jacquelot N., Chaba K., Mortier E., Jacques Y., Caillat-Zucman S., Flament C., et al. Regulation of CD4(+)NKG2D(+) Th1 cells in patients with metastatic melanoma treated with sorafenib: role of IL-15Rα and NKG2D triggering. Cancer Res. 2014, 74:68-80.
153. Rooney M.S., Shukla S.A., Wu C.J., Getz G., Hacohen N. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 2015, 160:48-61.
154. Roselli M., Cereda V., di Bari M.G., Formica V., Spila A., Jochems C., Farsaci B., Donahue R., Gulley J.L., Schlom J., Guadagni F. Effects of conventional therapeutic interventions on the number and function of regulatory T cells. OncoImmunology 2013, 2:e27025.
155. Ruddle N.H. Lymphatic vessels and tertiary lymphoid organs. J. Clin. Invest. 2014, 124:953-959.
156. Ruffell B., Au A., Rugo H.S., Esserman L.J., Hwang E.S., Coussens L.M. Leukocyte composition of human breast cancer. Proc. Natl. Acad. Sci. USA 2012, 109:2796-2801.
157. Ruffell B., Chang-Strachan D., Chan V., Rosenbusch A., Ho C.M., Pryer N., Daniel D., Hwang E.S., Rugo H.S., Coussens L.M. Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells. Cancer Cell 2014, 26:623-637.
158. Rusakiewicz S., Semeraro M., Sarabi M., Desbois M., Locher C., Mendez R., Vimond N., Concha A., Garrido F., Isambert N., et al. Immune infiltrates are prognostic factors in localized gastrointestinal stromal tumors. Cancer Res. 2013, 73:3499-3510.
159. Sagiv-Barfi I., Kohrt H.E., Burckhardt L., Czerwinski D.K., Levy R. Ibrutinib enhances the antitumor immune response induced by intratumoral injection of a TLR9 ligand in mouse lymphoma. Blood 2015, 125:2079-2086.
160. Savikko J., Rintala J.M., Rintala S., Koskinen P. Epidermal growth factor receptor inhibition by erlotinib prevents vascular smooth muscle cell and monocyte-macrophage function in vitro. Transpl. Immunol. 2015, 32:175-178.
161. Sawant A., Schafer C.C., Jin T.H., Zmijewski J., Tse H.M., Roth J., Sun Z., Siegal G.P., Thannickal V.J., Grant S.C., et al. Enhancement of antitumor immunity in lung cancer by targeting myeloid-derived suppressor cell pathways. Cancer Res. 2013, 73:6609-6620.
162. Schiavoni G., Sistigu A., Valentini M., Mattei F., Sestili P., Spadaro F., Sanchez M., Lorenzi S., D'Urso M.T., Belardelli F., et al. Cyclophosphamide synergizes with type I interferons through systemic dendritic cell reactivation and induction of immunogenic tumor apoptosis. Cancer Res. 2011, 71:768-778.
163. Schreiber R.D., Old L.J., Smyth M.J. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011, 331:1565-1570.
164. Sconocchia G., Zlobec I., Lugli A., Calabrese D., Iezzi G., Karamitopoulou E., Patsouris E.S., Peros G., Horcic M., Tornillo L., et al. Tumor infiltration by FcγRIII (CD16)+ myeloid cells is associated with improved survival in patients with colorectal carcinoma. Int. J. Cancer 2011, 128:2663-2672.
165. Senovilla L., Vacchelli E., Galon J., Adjemian S., Eggermont A., Fridman W.H., Sautès-Fridman C., Ma Y., Tartour E., Zitvogel L., et al. Trial watch: Prognostic and predictive value of the immune infiltrate in cancer. OncoImmunology 2012, 1:1323-1343.
166. Senovilla L., Vitale I., Martins I., Tailler M., Pailleret C., Michaud M., Galluzzi L., Adjemian S., Kepp O., Niso-Santano M., et al. An immunosurveillance mechanism controls cancer cell ploidy. Science 2012, 337:1678-1684.
167. Sevko A., Michels T., Vrohlings M., Umansky L., Beckhove P., Kato M., Shurin G.V., Shurin M.R., Umansky V. Antitumor effect of paclitaxel is mediated by inhibition of myeloid-derived suppressor cells and chronic inflammation in the spontaneous melanoma model. J. Immunol. 2013, 190:2464-2471.
168. Shalapour S., Font-Burgada J., Di Caro G., Zhong Z., Sanchez-Lopez E., Dhar D., Willimsky G., Ammirante M., Strasner A., Hansel D.E., et al. Immunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapy. Nature 2015, 521:94-98.
169. Shekarian T., Valsesia-Wittmann S., Caux C., Marabelle A. Paradigm shift in oncology: targeting the immune system rather than cancer cells. Mutagenesis 2015, 30:205-211.
170. Sistigu A., Yamazaki T., Vacchelli E., Chaba K., Enot D.P., Adam J., Vitale I., Goubar A., Baracco E.E., Remédios C., et al. Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat. Med. 2014, 20:1301-1309.
171. Skoetz N., Trelle S., Rancea M., Haverkamp H., Diehl V., Engert A., Borchmann P. Effect of initial treatment strategy on survival of patients with advanced-stage Hodgkin's lymphoma: a systematic review and network meta-analysis. Lancet Oncol. 2013, 14:943-952.
172. Soeda A., Morita-Hoshi Y., Makiyama H., Morizane C., Ueno H., Ikeda M., Okusaka T., Yamagata S., Takahashi N., Hyodo I., et al. Regular dose of gemcitabine induces an increase in CD14+ monocytes and CD11c+ dendritic cells in patients with advanced pancreatic cancer. Jpn. J. Clin. Oncol. 2009, 39:797-806.
173. Solimini N.L., Luo J., Elledge S.J. Non-oncogene addiction and the stress phenotype of cancer cells. Cell 2007, 130:986-988.
174. Spisek R., Charalambous A., Mazumder A., Vesole D.H., Jagannath S., Dhodapkar M.V. Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications. Blood 2007, 109:4839-4845.
175. Stagg J., Loi S., Divisekera U., Ngiow S.F., Duret H., Yagita H., Teng M.W., Smyth M.J. Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. Proc. Natl. Acad. Sci. USA 2011, 108:7142-7147.
176. Steinberg S.M., Zhang P., Malik B.T., Boni A., Shabaneh T.B., Byrne K.T., Mullins D.W., Brinckerhoff C.E., Ernstoff M.S., Bosenberg M.W., Turk M.J. BRAF inhibition alleviates immune suppression in murine autochthonous melanoma. Cancer Immunol. Res. 2014, 2:1044-1050.
177. Steinman R.M., Banchereau J. Taking dendritic cells into medicine. Nature 2007, 449:419-426.
178. Suzuki E., Kapoor V., Jassar A.S., Kaiser L.R., Albelda S.M. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin. Cancer Res. 2005, 11:6713-6721.
179. Taylor R.J., Saloura V., Jain A., Goloubeva O., Wong S., Kronsberg S., Nagilla M., Silpino L., de Souza J., Seiwert T., et al. Ex vivo antibody-dependent cellular cytotoxicity inducibility predicts efficacy of cetuximab. Cancer Immunol. Res. 2015, 3:567-574.
180. Terme M., Pernot S., Marcheteau E., Sandoval F., Benhamouda N., Colussi O., Dubreuil O., Carpentier A.F., Tartour E., Taieb J. VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer. Cancer Res. 2013, 73:539-549.
181. Tesniere A., Schlemmer F., Boige V., Kepp O., Martins I., Ghiringhelli F., Aymeric L., Michaud M., Apetoh L., Barault L., et al. Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene 2010, 29:482-491.
182. Tsang J.Y., Hui S.W., Ni Y.B., Chan S.K., Yamaguchi R., Kwong A., Law B.K., Tse G.M. Lymphocytic infiltrate is associated with favorable biomarkers profile in HER2-overexpressing breast cancers and adverse biomarker profile in ER-positive breast cancers. Breast Cancer Res. Treat. 2014, 143:1-9.
183. Vacchelli E., Aranda F., Eggermont A., Galon J., Sautès-Fridman C., Cremer I., Zitvogel L., Kroemer G., Galluzzi L. Trial Watch: Chemotherapy with immunogenic cell death inducers. OncoImmunology 2014, 3:e27878.
184. Vacchelli E., Aranda F., Eggermont A., Galon J., Sautès-Fridman C., Zitvogel L., Kroemer G., Galluzzi L. Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy. OncoImmunology 2014, 3:e27048.
185. Valent A., Penault-Llorca F., Cayre A., Kroemer G. Change in HER2 (ERBB2) gene status after taxane-based chemotherapy for breast cancer: polyploidization can lead to diagnostic pitfalls with potential impact for clinical management. Cancer Genet. 2013, 206:37-41.
186. van der Sluis T.C., van Duikeren S., Huppelschoten S., Jordanova E.S., Beyranvand Nejad E., Sloots A., Boon L., Smit V.T., Welters M.J., Ossendorp F., et al. Vaccine-induced tumor necrosis factor-producing T cells synergize with cisplatin to promote tumor cell death. Clin. Cancer Res. 2015, 21:781-794.
187. Vesely M.D., Kershaw M.H., Schreiber R.D., Smyth M.J. Natural innate and adaptive immunity to cancer. Annu. Rev. Immunol. 2011, 29:235-271.
188. Viaud S., Saccheri F., Mignot G., Yamazaki T., Daillère R., Hannani D., Enot D.P., Pfirschke C., Engblom C., Pittet M.J., et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science 2013, 342:971-976.
189. Vincent J., Mignot G., Chalmin F., Ladoire S., Bruchard M., Chevriaux A., Martin F., Apetoh L., Rébé C., Ghiringhelli F. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res. 2010, 70:3052-3061.
190. Vivier E., Raulet D.H., Moretta A., Caligiuri M.A., Zitvogel L., Lanier L.L., Yokoyama W.M., Ugolini S. Innate or adaptive immunity? The example of natural killer cells. Science 2011, 331:44-49.
191. Volk-Draper L., Hall K., Griggs C., Rajput S., Kohio P., DeNardo D., Ran S. Paclitaxel therapy promotes breast cancer metastasis in a TLR4-dependent manner. Cancer Res. 2014, 74:5421-5434.
192. Voron T., Colussi O., Marcheteau E., Pernot S., Nizard M., Pointet A.L., Latreche S., Bergaya S., Benhamouda N., Tanchot C., et al. VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors. J. Exp. Med. 2015, 212:139-148.
193. Wang B., Xu D., Yu X., Ding T., Rao H., Zhan Y., Zheng L., Li L. Association of intra-tumoral infiltrating macrophages and regulatory T cells is an independent prognostic factor in gastric cancer after radical resection. Ann. Surg. Oncol. 2011, 18:2585-2593.
194. Wang Q., Li S.H., Wang H., Xiao Y., Sahin O., Brady S.W., Li P., Ge H., Jaffee E.M., Muller W.J., et al. Concomitant targeting of tumor cells and induction of T-cell response synergizes to effectively inhibit trastuzumab-resistant breast cancer. Cancer Res. 2012, 72:4417-4428.
195. Wang M.L., Rule S., Martin P., Goy A., Auer R., Kahl B.S., Jurczak W., Advani R.H., Romaguera J.E., Williams M.E., et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N. Engl. J. Med. 2013, 369:507-516.
196. Wang Y., Sparwasser T., Figlin R., Kim H.L. Foxp3+ T cells inhibit antitumor immune memory modulated by mTOR inhibition. Cancer Res. 2014, 74:2217-2228.
197. Werner H.M., Mills G.B., Ram P.T. Cancer Systems Biology: a peek into the future of patient care?. Nat. Rev. Clin. Oncol. 2014, 11:167-176.
198. West A.C., Mattarollo S.R., Shortt J., Cluse L.A., Christiansen A.J., Smyth M.J., Johnstone R.W. An intact immune system is required for the anticancer activities of histone deacetylase inhibitors. Cancer Res. 2013, 73:7265-7276.
199. Westin J.R., Chu F., Zhang M., Fayad L.E., Kwak L.W., Fowler N., Romaguera J., Hagemeister F., Fanale M., Samaniego F., et al. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol. 2014, 15:69-77.
200. Whitehurst A.W. Cause and consequence of cancer/testis antigen activation in cancer. Annu. Rev. Pharmacol. Toxicol. 2014, 54:251-272.
201. Wilmott J.S., Long G.V., Howle J.R., Haydu L.E., Sharma R.N., Thompson J.F., Kefford R.F., Hersey P., Scolyer R.A. Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin. Cancer Res. 2012, 18:1386-1394.
202. Wu J., Waxman D.J. Metronomic cyclophosphamide eradicates large implanted GL261 gliomas by activating antitumor Cd8(+) T-cell responses and immune memory. OncoImmunology 2015, 4:e1005521.
203. Wumkes M.L., van der Velden A.M., Los M., Leys M.B., Beeker A., Nijziel M.R., van der Velden A.W., Westerman M., Meerveld-Eggink A., Rimmelzwaan G.F., et al. Serum antibody response to influenza virus vaccination during chemotherapy treatment in adult patients with solid tumours. Vaccine 2013, 31:6177-6184.
204. Xu X., Rao G.S., Groh V., Spies T., Gattuso P., Kaufman H.L., Plate J., Prinz R.A. Major histocompatibility complex class I-related chain A/B (MICA/B) expression in tumor tissue and serum of pancreatic cancer: role of uric acid accumulation in gemcitabine-induced MICA/B expression. BMC Cancer 2011, 11:194.
205. Yamazaki T., Hannani D., Poirier-Colame V., Ladoire S., Locher C., Sistigu A., Prada N., Adjemian S., Catani J.P., Freudenberg M., et al. Defective immunogenic cell death of HMGB1-deficient tumors: compensatory therapy with TLR4 agonists. Cell Death Differ. 2014, 21:69-78.
206. Zeng H., Yang K., Cloer C., Neale G., Vogel P., Chi H. mTORC1 couples immune signals and metabolic programming to establish T(reg)-cell function. Nature 2013, 499:485-490.
207. Zhu X.J., Yang Z.F., Zhou J.Y., Liu L., Sun X.M., Fan Z.F., Hu S.Y., Chen Y.C., Li W.X., Cao M., Wang L.X. Progression of Large Lymphoma Is Significantly Impeded with a Combination of Gemcitabine Chemotherapy and Dendritic Cells Intra-Tumor Vaccination. PLoS ONE 2015, 10:e0132799.
208. Zitvogel L., Tesniere A., Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat. Rev. Immunol. 2006, 6:715-727.
209. Zitvogel L., Galluzzi L., Smyth M.J., Kroemer G. Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity 2013, 39:74-88.
210. Zitvogel L., Galluzzi L., Kepp O., Smyth M.J., Kroemer G. Type I interferons in anticancer immunity. Nat. Rev. Immunol. 2015, 15:405-414.